TGFB1 and cancer: However, a failure in mDC activation in microenvironments dominated by immunomodulatory molecules (e.g., TGFβ and IL-10) and cells (such as Tregs) can promote a mDC tolerogenic phenotype, inducing T cell anergy upon antigen presentation, which is a frequent process in cancer, especially in well-known cold tumors with decreased mutational burden171, as is the case for gliomas172.